- Sir Peter MacCallum Department of Oncology - Research Publications
Sir Peter MacCallum Department of Oncology - Research Publications
Permanent URI for this collection
113 results
Filters
Reset filtersSettings
Statistics
Citations
Search Results
Now showing
1 - 10 of 113
-
ItemA comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primaryPosner, A ; Prall, OW ; Sivakumaran, T ; Etemadamoghadam, D ; Thio, N ; Pattison, A ; Balachander, S ; Fisher, K ; Webb, S ; Wood, C ; DeFazio, A ; Wilcken, N ; Gao, B ; Karapetis, CS ; Singh, M ; Collins, IM ; Richardson, G ; Steer, C ; Warren, M ; Karanth, N ; Wright, G ; Williams, S ; George, J ; Hicks, RJ ; Boussioutas, A ; Gill, AJ ; Solomon, BJ ; Xu, H ; Fellowes, A ; Fox, SB ; Schofield, P ; Bowtell, D ; Mileshkin, L ; Tothill, RW (WILEY, 2022-11-30)
-
ItemBeating the odds: molecular characteristics of long-term survivors of ovarian cancerGarsed, DW ; Bowtell, DDL (Nature Research, 2022-12-01)High-grade serous ovarian cancer, the most common form of the disease, is often fatal. This study investigated the genomic and immune characteristics of tumors from women who survived more than 10 years after their initial diagnosis, and compared them with short-term and moderate-term survivors.
-
ItemNo Preview AvailableCCNE1 Amplification as a Therapeutic TargetAu-Yeung, G ; Mileshkin, L ; Bowtell, DDL (LIPPINCOTT WILLIAMS & WILKINS, 2023-03-20)
-
ItemThe genomic and immune landscape of long-term survivors of high-grade serous ovarian cancerGarsed, DW ; Pandey, A ; Fereday, S ; Kennedy, CJ ; Takahashi, K ; Alsop, K ; Hamilton, PT ; Hendley, J ; Chiew, Y-E ; Traficante, N ; Provan, P ; Ariyaratne, D ; Au-Yeung, G ; Bateman, NW ; Bowes, L ; Brand, A ; Christie, EL ; Cunningham, JM ; Friedlander, M ; Grout, B ; Harnett, P ; Hung, J ; McCauley, B ; McNally, O ; Piskorz, AM ; Saner, FAM ; Vierkant, RA ; Wang, C ; Winham, SJ ; Pharoah, PDP ; Brenton, JD ; Conrads, TP ; Maxwell, GL ; Ramus, SJ ; Pearce, CL ; Pike, MC ; Nelson, BH ; Goode, EL ; DeFazio, A ; Bowtell, DDL (NATURE PORTFOLIO, 2022-12)Fewer than half of all patients with advanced-stage high-grade serous ovarian cancers (HGSCs) survive more than five years after diagnosis, but those who have an exceptionally long survival could provide insights into tumor biology and therapeutic approaches. We analyzed 60 patients with advanced-stage HGSC who survived more than 10 years after diagnosis using whole-genome sequencing, transcriptome and methylome profiling of their primary tumor samples, comparing this data to 66 short- or moderate-term survivors. Tumors of long-term survivors were more likely to have multiple alterations in genes associated with DNA repair and more frequent somatic variants resulting in an increased predicted neoantigen load. Patients clustered into survival groups based on genomic and immune cell signatures, including three subsets of patients with BRCA1 alterations with distinctly different outcomes. Specific combinations of germline and somatic gene alterations, tumor cell phenotypes and differential immune responses appear to contribute to long-term survival in HGSC.
-
ItemNo Preview AvailableOvarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2O'Mahony, DG ; Ramus, SJ ; Southey, MC ; Meagher, NS ; Hadjisavvas, A ; John, EM ; Hamann, U ; Imyanitov, EN ; Andrulis, IL ; Sharma, P ; Daly, MB ; Hake, CR ; Weitzel, JN ; Jakubowska, A ; Godwin, AK ; Arason, A ; Bane, A ; Simard, J ; Soucy, P ; Caligo, MA ; Mai, PL ; Claes, KBM ; Teixeira, MR ; Chung, WK ; Lazaro, C ; Hulick, PJ ; Toland, AE ; Pedersen, IS ; Neuhausen, SL ; Vega, A ; de la Hoya, M ; Nevanlinna, H ; Dhawan, M ; Zampiga, V ; Danesi, R ; Varesco, L ; Gismondi, V ; Vellone, VG ; James, PA ; Janavicius, R ; Nikitina-Zake, L ; Nielsen, FC ; van Overeem Hansen, T ; Pejovic, T ; Borg, A ; Rantala, J ; Offit, K ; Montagna, M ; Nathanson, KL ; Domchek, SM ; Osorio, A ; Garcia, MJ ; Karlan, BY ; De Fazio, A ; Bowtell, D ; McGuffog, L ; Leslie, G ; Parsons, MT ; Doerk, T ; Speith, L-M ; dos Santos, ES ; da Costa, AABA ; Radice, P ; Peterlongo, P ; Papi, L ; Engel, C ; Hahnen, E ; Schmutzler, RK ; Wappenschmidt, B ; Easton, DF ; Tischkowitz, M ; Singer, CF ; Tan, YY ; Whittemore, AS ; Sieh, W ; Brenton, JD ; Yannoukakos, D ; Fostira, F ; Konstantopoulou, I ; Soukupova, J ; Vocka, M ; Chenevix-Trench, G ; Pharoah, PDP ; Antoniou, AC ; Goldgar, DE ; Spurdle, AB ; Michailidou, K ; Mourits, MJE ; Lesueur, F (SPRINGERNATURE, 2023-06-29)BACKGROUND: The distribution of ovarian tumour characteristics differs between germline BRCA1 and BRCA2 pathogenic variant carriers and non-carriers. In this study, we assessed the utility of ovarian tumour characteristics as predictors of BRCA1 and BRCA2 variant pathogenicity, for application using the American College of Medical Genetics and the Association for Molecular Pathology (ACMG/AMP) variant classification system. METHODS: Data for 10,373 ovarian cancer cases, including carriers and non-carriers of BRCA1 or BRCA2 pathogenic variants, were collected from unpublished international cohorts and consortia and published studies. Likelihood ratios (LR) were calculated for the association of ovarian cancer histology and other characteristics, with BRCA1 and BRCA2 variant pathogenicity. Estimates were aligned to ACMG/AMP code strengths (supporting, moderate, strong). RESULTS: No histological subtype provided informative ACMG/AMP evidence in favour of BRCA1 and BRCA2 variant pathogenicity. Evidence against variant pathogenicity was estimated for the mucinous and clear cell histologies (supporting) and borderline cases (moderate). Refined associations are provided according to tumour grade, invasion and age at diagnosis. CONCLUSIONS: We provide detailed estimates for predicting BRCA1 and BRCA2 variant pathogenicity based on ovarian tumour characteristics. This evidence can be combined with other variant information under the ACMG/AMP classification system, to improve classification and carrier clinical management.
-
ItemNo Preview AvailableProfiling the immune landscape in mucinous ovarian carcinomaMeagher, NS ; Hamilton, P ; Milne, K ; Thornton, S ; Harris, B ; Weir, A ; Alsop, J ; Bisinoto, C ; Brenton, JD ; Brooks-Wilsoni, A ; Chiu, DS ; Cushing-Haugen, KL ; Fereday, S ; Garsed, DW ; Gayther, SA ; Gentry-Maharaj, A ; Gilks, B ; Jimenez-Linan, M ; Kennedy, CJ ; Le, ND ; Piskorz, AM ; Riggan, MJ ; Shah, M ; Singh, N ; Talhoukj, A ; Widschwendter, M ; Bowtell, DDL ; dos Reis, FJC ; Cook, LS ; Fortner, RT ; Garcia, MJ ; Harris, HR ; Huntsman, DG ; Karnezis, AN ; Kobel, M ; Menon, U ; Pharoah, PDP ; Doherty, JA ; Anglesioj, MS ; Pike, MC ; Pearce, CL ; Friedlander, ML ; DeFazio, A ; Nelson, BH ; Ramus, SJ (ACADEMIC PRESS INC ELSEVIER SCIENCE, 2023-01)OBJECTIVE: Mucinous ovarian carcinoma (MOC) is a rare histotype of ovarian cancer, with low response rates to standard chemotherapy, and very poor survival for patients diagnosed at advanced stage. There is a limited understanding of the MOC immune landscape, and consequently whether immune checkpoint inhibitors could be considered for a subset of patients. METHODS: We performed multicolor immunohistochemistry (IHC) and immunofluorescence (IF) on tissue microarrays in a cohort of 126 MOC patients. Cell densities were calculated in the epithelial and stromal components for tumor-associated macrophages (CD68+/PD-L1+, CD68+/PD-L1-), T cells (CD3+/CD8-, CD3+/CD8+), putative T-regulatory cells (Tregs, FOXP3+), B cells (CD20+/CD79A+), plasma cells (CD20-/CD79a+), and PD-L1+ and PD-1+ cells, and compared these values with clinical factors. Univariate and multivariable Cox Proportional Hazards assessed overall survival. Unsupervised k-means clustering identified patient subsets with common patterns of immune cell infiltration. RESULTS: Mean densities of PD1+ cells, PD-L1- macrophages, CD4+ and CD8+ T cells, and FOXP3+ Tregs were higher in the stroma compared to the epithelium. Tumors from advanced (Stage III/IV) MOC had greater epithelial infiltration of PD-L1- macrophages, and fewer PD-L1+ macrophages compared with Stage I/II cancers (p = 0.004 and p = 0.014 respectively). Patients with high epithelial density of FOXP3+ cells, CD8+/FOXP3+ cells, or PD-L1- macrophages, had poorer survival, and high epithelial CD79a + plasma cells conferred better survival, all upon univariate analysis only. Clustering showed that most MOC (86%) had an immune depleted (cold) phenotype, with only a small proportion (11/76,14%) considered immune inflamed (hot) based on T cell and PD-L1 infiltrates. CONCLUSION: In summary, MOCs are mostly immunogenically 'cold', suggesting they may have limited response to current immunotherapies.
-
ItemNo Preview AvailableLifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgeryPhung, MT ; Webb, PM ; DeFazio, A ; Fereday, S ; Lee, AW ; Bowtell, DDL ; Fasching, PA ; Goode, EL ; Goodman, MT ; Karlan, BY ; Lester, J ; Matsuo, K ; Modugno, F ; Brenton, JD ; Van Gorp, T ; Pharoah, PDP ; Schildkraut, JM ; McLean, K ; Meza, R ; Mukherjee, B ; Richardson, J ; Grout, B ; Chase, A ; Deurloo, CM ; Terry, KL ; Hanley, GE ; Pike, MC ; Berchuck, A ; Ramus, SJ ; Pearce, CL ; Ovarian, CAC (ACADEMIC PRESS INC ELSEVIER SCIENCE, 2023-01)OBJECTIVE: The presence of macroscopic residual disease after primary cytoreductive surgery (PCS) is an important factor influencing survival for patients with high-grade serous ovarian cancer (HGSC). More research is needed to identify factors associated with having macroscopic residual disease. We analyzed 12 lifestyle and personal exposures known to be related to ovarian cancer risk or inflammation to identify those associated with having residual disease after surgery. METHODS: This analysis used data on 2054 patients with advanced stage HGSC from the Ovarian Cancer Association Consortium. The exposures were body mass index, breastfeeding, oral contraceptive use, depot-medroxyprogesterone acetate use, endometriosis, first-degree family history of ovarian cancer, incomplete pregnancy, menopausal hormone therapy use, menopausal status, parity, smoking, and tubal ligation. Logistic regression models were fit to assess the association between these exposures and having residual disease following PCS. RESULTS: Menopausal estrogen-only therapy (ET) use was associated with 33% lower odds of having macroscopic residual disease compared to never use (OR = 0.67, 95%CI 0.46-0.97, p = 0.033). Compared to nulliparous women, parous women who did not breastfeed had 36% lower odds of having residual disease (OR = 0.64, 95%CI 0.43-0.94, p = 0.022), while there was no association among parous women who breastfed (OR = 0.90, 95%CI 0.65-1.25, p = 0.53). CONCLUSIONS: The association between ET and having no macroscopic residual disease is plausible given a strong underlying biologic hypothesis between this exposure and diagnosis with HGSC. If this or the parity finding is replicated, these factors could be included in risk stratification models to determine whether HGSC patients should receive PCS or neoadjuvant chemotherapy.
-
ItemNo Preview AvailableCCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium studyKang, E-Y ; Weir, A ; Meagher, NS ; Farrington, K ; Nelson, GS ; Ghatage, P ; Lee, C-H ; Riggan, MJ ; Bolithon, A ; Popovic, G ; Leung, B ; Tang, K ; Lambie, N ; Millstein, J ; Alsop, J ; Anglesio, MS ; Ataseven, B ; Barlow, E ; Beckmann, MW ; Berger, J ; Bisinotto, C ; Boesmueller, H ; Boros, J ; Brand, AH ; Brooks-Wilson, A ; Brucker, SY ; Carney, ME ; Casablanca, Y ; Cazorla-Jimenez, A ; Cohen, PA ; Conrads, TP ; Cook, LS ; Coulson, P ; Courtney-Brooks, M ; Cramer, DW ; Crowe, P ; Cunningham, JM ; Cybulski, C ; Darcy, KM ; El-Bahrawy, MA ; Elishaev, E ; Erber, R ; Farrell, R ; Fereday, S ; Fischer, A ; Garcia, MJ ; Gayther, SA ; Gentry-Maharaj, A ; Gilks, CB ; Grube, M ; Harnett, PR ; Harrington, SP ; Harter, P ; Hartmann, A ; Hecht, JL ; Heikaus, S ; Hein, A ; Heitz, F ; Hendley, J ; Hernandez, BY ; Hernando Polo, S ; Heublein, S ; Hirasawa, A ; Hogdall, E ; Hogdall, CK ; Horlings, HM ; Huntsman, DG ; Huzarski, T ; Jewell, A ; Jimenez-Linan, M ; Jones, ME ; Kaufmann, SH ; Kennedy, CJ ; Khabele, D ; Kommoss, FKF ; Kruitwagen, RFPM ; Lambrechts, D ; Le, ND ; Lener, M ; Lester, J ; Leung, Y ; Linder, A ; Loverix, L ; Lubinski, J ; Madan, R ; Maxwell, GL ; Modugno, F ; Neuhausen, SL ; Olawaiye, A ; Olbrecht, S ; Orsulic, S ; Palacios, J ; Pearce, CL ; Pike, MC ; Quinn, CM ; Mohan, GR ; Rodriguez-Antona, C ; Ruebner, M ; Ryan, A ; Salfinger, SG ; Sasamoto, N ; Schildkraut, JM ; Schoemaker, MJ ; Shah, M ; Sharma, R ; Shvetsov, YB ; Singh, N ; Sonke, GS ; Steele, L ; Stewart, CJR ; Sundfeldt, K ; Swerdlow, AJ ; Talhouk, A ; Tan, A ; Taylor, SE ; Terry, KL ; Toloczko, A ; Traficante, N ; Van de Vijver, KK ; van der Aa, MA ; Van Gorp, T ; Van Nieuwenhuysen, E ; Van-Wagensveld, L ; Vergote, I ; Vierkant, RA ; Wang, C ; Wilkens, LR ; Winham, SJ ; Wu, AH ; Benitez, J ; Berchuck, A ; Candido Dos Reis, FJ ; DeFazio, A ; Fasching, PA ; Goode, EL ; Goodman, MT ; Gronwald, J ; Karlan, BY ; Kommoss, S ; Menon, U ; Sinn, H-P ; Staebler, A ; Brenton, JD ; Bowtell, DD ; Pharoah, PDP ; Ramus, SJ ; Kobel, M (WILEY, 2023-03-01)BACKGROUND: Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo-ovarian high-grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression with survival, but to date no large-scale, histotype-specific validation has been performed. The hypothesis was that high-level amplification of CCNE1 and CCNE1 overexpression, as well as a combination of the two, are linked to shorter overall survival in HGSC. METHODS: Within the Ovarian Tumor Tissue Analysis consortium, amplification status and protein level in 3029 HGSC cases and mRNA expression in 2419 samples were investigated. RESULTS: High-level amplification (>8 copies by chromogenic in situ hybridization) was found in 8.6% of HGSC and overexpression (>60% with at least 5% demonstrating strong intensity by immunohistochemistry) was found in 22.4%. CCNE1 high-level amplification and overexpression both were linked to shorter overall survival in multivariate survival analysis adjusted for age and stage, with hazard stratification by study (hazard ratio [HR], 1.26; 95% CI, 1.08-1.47, p = .034, and HR, 1.18; 95% CI, 1.05-1.32, p = .015, respectively). This was also true for cases with combined high-level amplification/overexpression (HR, 1.26; 95% CI, 1.09-1.47, p = .033). CCNE1 mRNA expression was not associated with overall survival (HR, 1.00 per 1-SD increase; 95% CI, 0.94-1.06; p = .58). CCNE1 high-level amplification is mutually exclusive with the presence of germline BRCA1/2 pathogenic variants and shows an inverse association to RB1 loss. CONCLUSION: This study provides large-scale validation that CCNE1 high-level amplification is associated with shorter survival, supporting its utility as a prognostic biomarker in HGSC.
-
ItemOlder age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinomaPitiyarachchi, O ; Lee, YC ; Sim, H-W ; Srirangan, S ; Mapagu, C ; Kirk, J ; Harnett, PR ; Balleine, RL ; Bowtell, DDL ; Samimi, G ; Brand, AH ; Marsh, DJ ; Beale, P ; Anderson, L ; Bouantoun, N ; Provan, P ; Ramus, SJ ; DeFazio, A ; Friedlander, M ; INOVATe, I (ELSEVIER SCIENCE INC, 2023-02-18)BACKGROUND: Somatic pathogenic variants (PVs) in homologous recombination DNA repair (HR)-related genes found in high-grade serous ovarian carcinomas (HGSC) are not well-characterised in older patients (≥70 years). This may reflect low testing rates in older patients. METHODS: Data from 1210 HGSC patients in AACR Project GENIE and 324 patients in an independent dataset INOVATe were analysed. Cases where somatic variants could be distinguished from germline variants were included, and analysis was restricted to those with a somatic TP53 variant, to ensure cases were HGSC. RESULTS: Of 1210 patients in GENIE, 27% (n = 325) were aged ≥70 years at testing. Patients with somatic-only PVs in BRCA2 were older compared with BRCA1 (median 71 vs 60 years, p = 0.002). Median age for 21 patients with somatic-only PVs in 11 other HR-related genes ranged from 40 to 67 years. In older patients, 7% (n = 22) had somatic BRCA1/2 PVs, and 1% (n = 2) had PVs other HR-related genes; this rate was not significantly different to younger patients (<70 years), 7% (n = 62) BRCA1/2 and 2% (n = 19) other HR-related genes (p = 0.36). The overall frequency of somatic BRCA1/2 PVs was similar in INOVATe (n = 25; 7.7%) and somatic-only BRCA2 PVs were again found in older patients compared with BRCA1 (median age: at testing, 70 vs 63 years; at diagnosis, 68 vs 60 years). CONCLUSIONS: The overall frequency of somatic-only PVs in HR-related genes was similar in older and younger patients with HGSC, highlighting the importance of somatic testing irrespective of age. Limiting somatic testing by age may exclude patients who could benefit from maintenance poly(ADP-ribose) polymerase (PARP) inhibitors.
-
ItemIncreased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium StudyWeir, A ; Kang, E-Y ; Meagher, NS ; Nelson, GS ; Ghatage, P ; Lee, C-H ; Riggan, MJ ; Gentry-Maharaj, A ; Ryan, A ; Singh, N ; Widschwendter, M ; Alsop, J ; Anglesio, MS ; Beckmann, MW ; Berger, J ; Bisinotto, C ; Boros, J ; Brand, AH ; Brenton, JD ; Brooks-Wilson, A ; Carney, ME ; Cunningham, JM ; Cushing-Haugen, KL ; Cybulski, C ; Elishaev, E ; Erber, R ; Fereday, S ; Fischer, A ; Paz-Ares, L ; Gayarre, J ; Gilks, BC ; Grube, M ; Harnett, PR ; Harris, HR ; Hartmann, A ; Hein, A ; Hendley, J ; Hernandez, BY ; Heublein, S ; Huang, Y ; Huzarski, T ; Jakubowska, A ; Jimenez-Linan, M ; Kennedy, CJ ; Kommoss, FKF ; Koziak, JM ; Kraemer, B ; Le, ND ; Lesnock, J ; Lester, J ; Lubinski, J ; Menkiszak, J ; Ney, B ; Olawaiye, A ; Orsulic, S ; Osorio, A ; Robles-Diaz, L ; Ruebner, M ; Shah, M ; Sharma, R ; Shvetsov, YB ; Steed, H ; Talhouk, A ; Taylor, SE ; Traficante, N ; Vierkant, RA ; Wang, C ; Wilkens, LR ; Winham, SJ ; Benitez, J ; Berchuck, A ; Bowtell, DD ; Candido dos Reis, FJ ; Cook, LS ; DeFazio, A ; Doherty, JA ; Fasching, PA ; Garcia, MJ ; Goode, EL ; Goodman, MT ; Gronwald, J ; Huntsman, DG ; Karlan, BY ; Kommoss, S ; Modugno, F ; Schildkraut, JM ; Sinn, H-P ; Staebler, A ; Kelemen, LE ; Ford, CE ; Menon, U ; Pharoah, PDP ; Koebel, M ; Ramus, SJ ; Bowtell, D ; DeFazio, A ; Traficante, N ; Fereday, S ; Brand, A ; Harnett, P ; Sharma, R (SPRINGERNATURE, 2023-01-26)BACKGROUND: Recently, we showed a >60% difference in 5-year survival for patients with tubo-ovarian high-grade serous carcinoma (HGSC) when stratified by a 101-gene mRNA expression prognostic signature. Given the varied patient outcomes, this study aimed to translate prognostic mRNA markers into protein expression assays by immunohistochemistry and validate their survival association in HGSC. METHODS: Two prognostic genes, FOXJ1 and GMNN, were selected based on high-quality antibodies, correlation with protein expression and variation in immunohistochemical scores in a preliminary cohort (n = 134 and n = 80, respectively). Six thousand four hundred and thirty-four (FOXJ1) and 5470 (GMNN) formalin-fixed, paraffin-embedded ovarian neoplasms (4634 and 4185 HGSC, respectively) represented on tissue microarrays from the Ovarian Tumor Tissue Analysis consortium underwent immunohistochemical staining and scoring, then univariate and multivariate survival analysis. RESULTS: Consistent with mRNA, FOXJ1 protein expression exhibited a linear, increasing association with improved overall survival in HGSC patients. Women with >50% expression had the most favourable outcomes (HR = 0.78, 95% CI 0.67-0.91, p < 0.0001). GMNN protein expression was not significantly associated with overall HSGC patient survival. However, HGSCs with >35% GMNN expression showed a trend for better outcomes, though this was not significant. CONCLUSION: We provide foundational evidence for the prognostic value of FOXJ1 in HGSC, validating the prior mRNA-based prognostic association by immunohistochemistry.